PNC Financial Services Group Inc. Has $352,000 Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

PNC Financial Services Group Inc. grew its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 5.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,891 shares of the biotechnology company’s stock after purchasing an additional 145 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Sarepta Therapeutics were worth $352,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Generali Investments CEE investicni spolecnost a.s. acquired a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at about $243,000. Inceptionr LLC acquired a new stake in Sarepta Therapeutics during the fourth quarter worth about $1,326,000. Arizona State Retirement System grew its position in Sarepta Therapeutics by 1.6% during the fourth quarter. Arizona State Retirement System now owns 24,890 shares of the biotechnology company’s stock worth $3,026,000 after buying an additional 394 shares in the last quarter. Proficio Capital Partners LLC acquired a new stake in Sarepta Therapeutics during the fourth quarter worth about $3,829,000. Finally, Assetmark Inc. grew its position in Sarepta Therapeutics by 9.6% during the fourth quarter. Assetmark Inc. now owns 42,759 shares of the biotechnology company’s stock worth $5,199,000 after buying an additional 3,734 shares in the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares of the company’s stock, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 7.70% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Needham & Company LLC reissued a “buy” rating and set a $202.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday. Scotiabank decreased their target price on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating on the stock in a research report on Thursday. Royal Bank of Canada decreased their target price on Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating on the stock in a research report on Thursday, February 27th. Piper Sandler decreased their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. Finally, HC Wainwright restated a “sell” rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $167.41.

Sarepta Therapeutics Stock Performance

SRPT stock opened at $74.10 on Friday. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The company has a 50 day moving average price of $107.19 and a 200 day moving average price of $118.11. Sarepta Therapeutics, Inc. has a fifty-two week low of $73.05 and a fifty-two week high of $173.25. The stock has a market capitalization of $7.19 billion, a PE ratio of 59.28 and a beta of 0.79.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.